Cytek Biosciences, Inc.
Cytek Biosciences designs and sells flow cytometry instruments, reagents, software and service offerings used to analyze cells for research and clinical applications. Its portfolio centers on full spectrum flow cytometry systems such as Cytek Aurora and Northern Lights, alongside conventional flow and image-based products acquired through the Luminex FCI business.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueFlow cytometry systems and related hardware sold for cell analysis and immunophenotyping.
Reagents, reagent kits, loaders and other recurring-use products tied to installed instruments.
Cytek Cloud, QbSure and other software tools that support panel design, acquisition and workflow management.
Post-warranty service contracts, installations, repairs and maintenance support.
Products
Reported · share of revenue- Products71.6 %
- Services28.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Cytek sells primarily to research and applied-life-science users that need high-parameter cell analysis, including academic and government institutions, CROs, pharmaceutical and biotechnology companies, and clinical laboratories. The company also serves entry-to-mid-range users through its Guava line and clinical research customers through products intended for disease detection, diagnosis support and treatment monitoring.
Buy instruments, reagents and software for basic research, immunology and cell biology; important for installed base and publications.
Use the platform for translational research, assay development and therapy monitoring, especially where high sensitivity matters.
Purchase systems to support outsourced research workflows that require reproducible cell analysis and client-facing throughput.
Adopt clinical-research-capable systems for disease detection, diagnosis support and monitoring applications.
Buy Guava systems for lower-cost, easier-to-use cell counting and lower-plex immunophenotyping.
Strategy
Cytek is trying to turn its installed base into recurring revenue by linking instruments with consumables, services and software. It is also pushing clinical research applications and expanding internationally, while continuing to invest in R&D, commercial infrastructure and the Cytek Cloud ecosystem.
Bundling instruments with reagents, software and services increases customer stickiness and recurring revenue.
Clinical use cases can broaden the addressable market and support higher-value applications.
Broader sales coverage is needed to convert scientific validation into revenue growth across regions.
New instruments and digital tools help defend against larger competitors and support premium positioning.
Geography
Q1/2026Cytek sells directly in North America, Europe, China and parts of Asia-Pacific, while also using distributors in parts of Europe, Latin America, the Middle East, Africa and Asia-Pacific. Manufacturing is spread across Fremont, Wuxi, Seattle and Singapore, which supports global supply but also creates exposure to trade controls, supplier concentration and cross-border logistics.
Share of the revenue the company reports by geography.
Risks
Cytek operates in a crowded cell analysis market where larger competitors have greater scale, brand recognition and R&D resources. Its business is also exposed to supplier concentration, export controls affecting China, and funding pressure from academic and government customers, which can make revenue more volatile and harder to scale profitably.
- Competitive pressure in flow cytometryImpact: HighLikelihood: Medium
The market includes large incumbents with deeper resources and established customer bases, which can limit pricing power and adoption.
Exposure - Supplier concentrationImpact: HighLikelihood: Medium
Key components such as lasers and semiconductors come from limited or sole-source suppliers, creating supply and cost risk.
Exposure: Manufacturing and product availability
- China export and regulatory exposureImpact: HighLikelihood: Medium
New U.S. export controls may affect products, technology transfer, manufacturing and R&D tied to China.
Exposure - Academic funding sensitivityImpact: MediumLikelihood: Medium
NIH indirect cost reimbursement changes can reduce purchasing capacity at academic and government customers.
Exposure: Academic and government demand
- Execution risk from limited operating historyImpact: Medium
The company has a relatively short commercial track record, making growth, margin and demand trends harder to predict.
Exposure: Commercial scaling and profitability
Accounting
Judgemental itemsInstrument revenue is recognized at transfer of control, while services are recognized over time, creating mix-driven volatility.
Impact: Quarterly revenue and gross margin can shift with shipment timing and service mix
Post-warranty contracts are recognized ratably, so deferred revenue and service backlog matter for forecasting.
Impact: Affects recurring revenue visibility
Operating leases for offices and facilities extend through 2029 and create fixed commitments.
Impact: Impacts operating expenses and cash flow
The Luminex FCI acquisition added Amnis and Guava assets that may carry intangible assets and goodwill.
Impact: Potential impairment risk and amortization pressure
Similar listed companies
Publicly listed companies with a comparable business focus.
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Natera, Inc.
NTRA · Services-Medical Laboratories
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
HUTCHMED (China) Ltd
HCM · Pharmaceutical Preparations
HUTCHMED (China) Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.
Maravai LifeSciences Holdings, Inc
MRVI · Pharmaceutical Preparations
CytoMed Therapeutics Ltd
GDTC · Pharmaceutical Preparations
CytoMed Therapeutics Ltd is a Singapore-based clinical-stage biopharmaceutical company developing donor-derived cell therapies for cancer.
Last updated: 24/09/2026